The curative efficacy ananlysis of dexmedetomidine-remifentanil during first-trimester surgical abortion of cesarean scar pregnancy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800018622

Enrollment

Unknown

Registered

2018-09-30

Start date

2018-11-01

Completion date

Unknown

Last updated

2018-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Interventions

PR group:propofol and remifentanil

DR group:dexmedetomidine and remifentanil

Eligibility

Sex/Gender

Female

Age

20 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. ASA I-II; 2. cesarean scar pregnancy and gestional age less than 10 6/7 weeks; 3. aged 20 to 35 years old; 4. be able to fully communicate; 5. to sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. preoperative combined with chronic pain and long-term use of analgesic drugs (included pelvic inflammatory disease); 2. severe heart,lung,liver and kidney dysfunction; 3. the history of neuromuscular diseases,endocrine system ddiseases,allergic diseases,and mental disorders; 4. given dexmedetomidine hydrochloride,propofol or remifentanil allergy; 5. preoperative received premedication with misoprostol.

Design outcomes

Primary

Measure	Time frame
the scores of pain;vital signs;drug consumption;	—

Secondary

Measure	Time frame
satisfaction assessment;motor responses during surgery;nausea and vomiting scores;	—

Countries

China

Contacts

Public ContactLimin Wei

Liaocheng People's Hospital, Liaocheng, Shandong

weilimin19860914@163.com+86 15069583861

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026